Tag Archives: drug safety

Track-and-Trace Not Enough to Halt Drug Counterfeiters

Despite recent legislation to establish a more secure pharmaceutical supply chain to deliver high quality, approved medicines to American patients, efforts to block the import of substandard, fraudulent, and counterfeit drugs remains an uphill fight. Criminals are expanding from “lifestyle” drugs to widely used anti-cholesterol and cancer medicines, attracted by huge profits and low risks […]
Posted in FDA, Regulatory, Safety, Supply Chain | Also tagged , , , , | Leave a comment

EU Tense as Crunch-Time for Counterfeits Approaches

By Reflector, Pharm Exec’s Brussels correspondent. Tensions are rising in Europe’s pharmaceutical sector as crunch-time approaches for the legislation to combat counterfeits. By this time next year, the European Commission is due to have decided on the mechanisms required to put into effect the European Union’s hugely complex new rules to keep falsified medicines out […]
Posted in Europe, Global, Guest Blog | Also tagged , , , , , | Leave a comment

Safety Trumps Access to Pain Meds for FDA

By Jill Wechsler, Washington Correspondent. The Food and Drug Administration has come down on the side of reducing abuse of opoid medications, over encouraging wider availability of low-cost painkiller meds. The agency decided to block generic versions of the original OxyContin formulation, which is fairly easy to manipulate by illegal users. The aim is to […]
Posted in Guest Blog, healthcare, Op-Ed, Regulatory, Safety | Also tagged , , | Leave a comment

"Sunshine" Just the Tip of the Iceberg: Pharma and Full Disclosure

“Sunshine” Just the Tip of the Iceberg: Full Disclosure for Pharma:??There seems no end to demands for data on clinical research, conflicts of interest, company payments, and drug prices, writes Jill Wechsler. Although recent legislation and regulations have greatly expanded the range of information that pharmaceutical companies have to unveil to the public, there’s an […]
Posted in Guest Blog, healthcare, Op-Ed, pricing, Regulatory, Safety, Strategy | Also tagged , , , | 1 Comment

Fixing Innovation: Lilly's CEO Says Why, and How

Following his keynote address last week at the Financial Times US Healthcare and Life Sciences Conference in New York, Eli Lilly CEO John Lechleiter huddled into a corridor to speak with PharmExec about his agenda as incoming chairman of PhRMA, and how to fix innovation.
Posted in Europe, Events, FDA, Global, healthcare, IP, leadership, Legal, Market Access, Meetings, People, pricing, R&D, Regulatory, Safety, Strategy, Technology | Also tagged , , , , , , , , , , , , | 1 Comment
  • Categories

  • Meta